All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.
GNE-7883 is a potent pan-TEAD small molecule inhibitor that inhibits the interaction between YAP/TAZ and TEAD through altered regulation. It possesses antiproliferative and antitumor activity and can be used in tumor-related studies.
| Molecular Weight | 500.57 |
| Formula | C28H29FN6O2 |
| CAS Number | 2648450-42-2 |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Connor A Ott et al. Trends Cancer. Targeting TEAD-ious resistance
| Related YAP Products |
|---|
| Verteporfin (CL 318952)
Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin (CL 318952) is a YAP inhibitor that disrupts YAP-TEAD interactions, and it is also an inhibitor of autophagy. |
| YAP-TEAD-IN-1 TFA
YAP-TEAD-IN-1 TFA is a competitive inhibitor of YAP-TEAD interaction with IC50 of 25 nM. |
| Super-TDU
Super-TDU is a specific YAP antagonist that targets YAP-TEAD interactions. Super-TDU can inhibit tumor growth in mouse models of gastric cancer. |
| TED-347
TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with an EC50 of 5.9 μM for TEAD4⋅Yap1 protein-protein interaction. |
| YAP/TAZ inhibitor-1
YAP/TAZ inhibitor-1 is a YAP/TAZ inhibitor with an IC50 of <0.100 μΜ in firefly luciferase assay. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
